Sarepta Therapeutics, Inc.
SRPT
$18.84
-$0.29-1.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 126.19% | -403.27% | -322.84% | -222.54% | -1,570.01% |
| Total Depreciation and Amortization | 15.86% | 18.02% | 28.68% | 3.31% | -6.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -11.94% | 62.02% | 58.84% | 47.62% | 270.98% |
| Change in Net Operating Assets | 66.14% | 110.89% | 47.91% | 15.61% | 1.89% |
| Cash from Operations | 132.03% | 0.15% | 30.60% | 24.15% | -2.52% |
| Capital Expenditure | 59.23% | 25.54% | -15.73% | -36.68% | -49.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -27.15% | -80.77% | 1,842.34% | 1,288.87% | 182.13% |
| Cash from Investing | -7.80% | -90.78% | 1,111.52% | 343.32% | 506.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -12,388.65% | -239,000.00% | -- | -- | -- |
| Issuance of Common Stock | -68.16% | -51.33% | -45.85% | -56.37% | 61.12% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -142.88% | -142.88% | -- | -- | -- |
| Cash from Financing | -256.83% | -234.88% | -203.07% | -35.27% | 153.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 218.62% | -145.09% | 218.73% | 126.92% | 58.37% |